Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial.
Schlenk RF, Benner A, Hartmann F, del Valle F, Weber C, Pralle H, Fischer JT, Gunzer U, Pezzutto A, Weber W, Grimminger W, Preiss J, Hensel M, Fröhling S, Döhner K, Haas R, Döhner H; AML Study Group Ulm (AMLSG ULM).
Schlenk RF, et al. Among authors: frohling s.
Leukemia. 2003 Aug;17(8):1521-8. doi: 10.1038/sj.leu.2403009.
Leukemia. 2003.
PMID: 12886238
Clinical Trial.